Reuters logo
BRIEF-Immunocellular Therapeutics provides update on ICT-107 phase 3 glioblastoma trial
March 6, 2017 / 11:32 AM / 6 months ago

BRIEF-Immunocellular Therapeutics provides update on ICT-107 phase 3 glioblastoma trial

March 6 (Reuters) - Immunocellular Therapeutics Ltd :

* Immunocellular Therapeutics provides update on ICT-107 phase 3 glioblastoma trial and announces advances in stem-to-t-cell research program

* Immunocellular Therapeutics Ltd - change in status of SPA will not materially impact execution of phase 3 trial

* Immunocellular Therapeutics Ltd - special protocol assessment (SPA) which was based on original protocol, is no longer applicable

* Immunocellular Therapeutics Ltd - will engage in further discussions with FDA concerning SPA in future Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below